Integra Lifesciences(DE:IL3)
€13.00+0.40 (+3.17%)
DE:IL3
Integra Lifesciences stock forecast
€13.00
At close:+0.40 (+3.17%)
Integra Lifesciences (IL3) Stock Forecast & Price Target
0 Followers
IL3 Analyst Ratings
Hold
1Buy6Hold2Sell
Based on 9 analysts giving stock ratings to Integra Lifesciences in the past 3 months
IL3 Stock 12 Month Forecast
Average Price Target
€13.29▲(2.25% Upside)Based on 9 Wall Street analysts offering 12 month price targets for Integra Lifesciences in the last 3 months. The average price target is EUR 13.29 with a high forecast of EUR 19.83 and a low forecast of EUR 11.72. The average price target represents a 2.25% change from the last price of EUR 13.00.
Past 12 Months12 Month ForecastJan2026Oct2026
High€19.83
Average€13.29
Low€11.72
Highest Price TargetHighest€19.83Average Price Target€13.29Lowest Price TargetLowest€11.72
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Patrick Wood | UBS | €17.12→€12.62 | hold | -2.95%Downside | Assigned | 10/27/26 | ||
| Ravi Misra | Truist Financial | €13.52→€11.72 | hold | -9.88%Downside | Reiterated | 10/26/26 | ||
| Larry Biegelsen | Wells Fargo | €13.52→€11.72 | hold | -9.88%Downside | Assigned | 10/22/26 | ||
| Daniel Stauder | Citizens JMP | €22.53→€19.83 | buy | 52.51%Upside | Reiterated | 10/22/26 | ||
| Travis Steed | Bank of America Securities | €12.62 | sell | -2.95%Downside | Reiterated | 10/22/26 | ||
| Joanne Wuensch | Citi | €13.52→€12.62 | hold | -2.95%Downside | Assigned | 10/22/26 | ||
| Vik Chopra | BMO Capital | €13.52→€12.62 | hold | -2.95%Downside | Reiterated | 10/22/26 | ||
| Robbie Marcus | J.P. Morgan | €15.32→€12.62 | sell | -2.95%Downside | Reiterated | 10/22/26 | ||
| Ryan Zimmerman | BTIG | ― | hold | ― | Reiterated | 10/21/26 | ||
| David Toung | Argus Research | €22.53 | buy | 73.30%Upside | Upgraded | 06/17/26 | ||
 Unknown AnalystNot Ranked | Jefferies | €24.33 | buy | 87.17%Upside | Reiterated | 05/06/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Patrick WoodUBS | HoldAssigned€17.12→€12.62 | 10/27/26 | -2.95%Downside | ||
| Ravi MisraTruist Financial | HoldReiterated€13.52→€11.72 | 10/26/26 | -9.88%Downside | ||
| Larry BiegelsenWells Fargo | HoldAssigned€13.52→€11.72 | 10/22/26 | -9.88%Downside | ||
| Daniel StauderCitizens JMP | BuyReiterated€22.53→€19.83 | 10/22/26 | 52.51%Upside | ||
| Travis SteedBank of America Securities | SellReiterated€12.62 | 10/22/26 | -2.95%Downside | ||
| Joanne WuenschCiti | HoldAssigned€13.52→€12.62 | 10/22/26 | -2.95%Downside | ||
| Vik ChopraBMO Capital | HoldReiterated€13.52→€12.62 | 10/22/26 | -2.95%Downside | ||
| Robbie MarcusJ.P. Morgan | SellReiterated€15.32→€12.62 | 10/22/26 | -2.95%Downside | ||
| Ryan ZimmermanBTIG | HoldReiterated | 10/21/26 | ― | ||
| David ToungArgus Research | BuyUpgraded€22.53 | 06/17/26 | 73.30%Upside | ||
| Unknown AnalystJefferiesNot Ranked | BuyReiterated€24.33 | 05/06/26 | 87.17%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Integra Lifesciences
3 Months
Success Rate6/11 ratings generated profit
55%
Average Return
-2.33%
Copying Robbie Marcus's trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of -2.33% per trade.
1 Year
Success Rate8/11 ratings generated profit
73%
Average Return
+17.73%
Copying Robbie Marcus's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +17.73% per trade.
2 Years
Success Rate7/11 ratings generated profit
64%
Average Return
+19.91%
Copying Robbie Marcus's trades and holding each position for 2 Years would result in 63.64% of your transactions generating a profit, with an average return of +19.91% per trade.
IL3 Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 0 | 1 | 1 |
| Buy | 1 | 1 | 0 | 0 | 0 |
| Hold | 10 | 8 | 7 | 13 | 12 |
| Sell | 2 | 1 | 1 | 3 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 14 | 10 | 8 | 17 | 15 |
In the current month, IL3 has received 1 Buy Ratings, 12 Hold Ratings, and 2 Sell Ratings. IL3 average Analyst price target in the past 3 months is 13.29.
IL3 Financial Forecast
High€0.60
Consensus€0.58
Low€0.55
IL3 Earnings Forecast
Next quarter’s earnings estimate for IL3 is EUR 0.58 with a range of EUR 0.55 to EUR 0.60. The previous quarter’s EPS was EUR 0.53. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High€380M
Consensus€378M
Low€376M
IL3 Sales Forecast
Next quarter’s sales forecast for IL3 is EUR 378.09M with a range of EUR 376.05M to EUR 379.54M. The previous quarter’s sales results were EUR 368.07M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
IL3 Stock Forecast FAQ
What is DE:IL3’s average 12-month price target, according to analysts?
Based on analyst ratings, Integra Lifesciences’s 12-month average price target is €13.29.
What is DE:IL3’s upside potential, based on the analysts’ average price target?
Integra Lifesciences has 2.25% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Integra Lifesciences a Buy, Sell or Hold?
Integra Lifesciences has a consensus rating of Hold, which is based on 1 buy ratings, 6 hold ratings and 2 sell ratings.
What is Integra Lifesciences’s share price target?
The average share price target for Integra Lifesciences is €13.29. This is based on 9 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €19.83, and the lowest forecast is €11.72. The average share price target represents a 2.25% increase from the current price of €13.
What do analysts say about Integra Lifesciences?
Integra Lifesciences’s analyst rating consensus is a Hold. This is based on the ratings of 9 Wall Street analysts.
How can I buy shares of Integra Lifesciences?
To buy shares of DE:IL3, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
